Catalyst Event
D&D Pharmatech Inc (347850) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
5/31/2026, 12:00:00 AM
Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled
Korean Translation
MASH 치료제 후보물질 DD01의 임상 2상 48주차 간 조직생검(biopsy) 데이터를 포함한 최종 탑라인(Top-line) 결과가 2026년 5월경 발표될 예정임. 임상 2상 결과 발표에 따른 10% 이상의 주가 변동 가능성으로 중요도를 'High'로 예상됨
Related Recent Events
SK Biopharmaceuticals Co Ltd (326030) · Other
The 14th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.
3/20/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.
3/18/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.
3/18/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.
3/16/2026, 12:00:00 AM
GC Cell Corporation (144510) · Earnings Release
Announced full-year 2025 earnings results, reporting a significant increase in net loss to KRW 272.9 billion from KRW 73.9 billion in the previous year. Basic loss per share widened to KRW 18,158 from KRW 4,918.
3/16/2026, 12:00:00 AM